In a retrospective study conducted by Sabrina et al., sarcopenia did not affect the response to gefitinib in patients with EGFR-mutated NSCLC, even though it was an indicator of poor prognosis in terms of OS (17). This evidence concerns the gene EGFR and non-small cell lung carcinoma.